A Phase II Trial of Neoadjuvant Chemoradiation (CRT) and Pembrolizumab in Patients With Rectal Cancer: Hoosier Cancer Research Network GI15-213

Trial Profile

A Phase II Trial of Neoadjuvant Chemoradiation (CRT) and Pembrolizumab in Patients With Rectal Cancer: Hoosier Cancer Research Network GI15-213

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Pembrolizumab (Primary) ; Capecitabine
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 22 Aug 2016 Planned initiation date changed from 1 Mar 2016 to 1 Sep 2016.
    • 04 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top